治疗公司（Therapeutics Inc.）是一家处于临床阶段的癌症药物制造商和技术公司，在美国首次公开募股（IPO）中筹集了1.5亿美元，发行价位于其营销区间的中点。
Therapeutics Inc., a clinical-stage cancer drugmaker and technology firm, raised $150 million in a US initial public offering that priced at the midpoint of its marketed range.
根据周三发布的声明，该公司持有英伟达（Nvidia Corp.）作为股东，以每股16美元的价格售出约938万股。此前的申报文件显示，Iambic曾计划以每股15至17美元的价格发行股份。
The firm, which counts Nvidia Corp. as a shareholder, sold about 9.38 million shares at $16 each, according to a statement Wednesday. Iambic had offered shares for $15 to $17 each, an earlier filing showed.
按IPO价格计算，总部位于圣地亚哥的公司根据申报文件中列出的流通股股份，市值为7.58亿美元。
At the IPO price, the San Diego-based firm has a market value of $758 million based on the outstanding shares listed in the filing.
申报文件显示，Iambic利用人工智能和机器学习来帮助其发现新疗法。公司计划将IPO所得用于推进三种早期阶段的癌症药物候选者。
Iambic uses AI and machine learning to help it discover new treatments, the filing shows. The company will use the proceeds from the IPO to advance three early-stage cancer drug candidates.
ARK投资管理公司（ARK Investment Management）已是Iambic的投资者，亿万富翁斯坦利·德鲁肯米勒（Stanley Druckenmiller）的杜克森家族办公室（Duquesne Family Office）表示有兴趣在此次发行中合计购买价值高达6000万美元的股份。
ARK Investment Management, which is already an investor in Iambic, and billionaire Stanley Druckenmiller’s Duquesne Family Office have expressed an interest in buying as much as $60 million worth of shares in the offering in aggregate.
这家专注于肿瘤学的公司正准备抓住投资者对人工智能有望加速生物发现潜力的热情。
The oncology-focused firm is poised to capitalize on investor excitement about the potential for artificial intelligence to speed up biological discoveries.
申报文件显示，总部位于圣地亚哥的公司与艾伯维公司（Abbvie Inc.）合作，以加速免疫学、神经科学和肿瘤学领域的人工智能驱动的药物发现，并与武田药品工业株式会社（Takeda Pharmaceutical Co.）和H.隆贝克 A/S（H. Lundbeck A/S）等药企建立了合作关系。Iambic还将英伟达和人工智能云公司Lambda Inc.列为其合作伙伴之一。
The San Diego-based firm partnered with Abbvie Inc. to accelerate AI-enabled drug discovery in immunology, neuroscience and oncology, and has relationships with drugmakers such as Takeda Pharmaceutical Co. and H. Lundbeck A/S, the filing showed. Iambic also counts Nvidia and AI cloud firm Lambda Inc. among its partners.
此前的申报文件显示，该药企在截至2026年6月30日的六个月内，收入为1280万美元，净亏损为5010万美元；而去年同期的收入为390万美元，净亏损为3320万美元。
The drugmaker had a net loss of $50.1 million on revenue of $12.8 million for the six months ended June 30, 2026, versus a net loss of $33.2 million on revenue of $3.9 million for the corresponding period a year before, a previous filing showed.
自2019年成立以来，Iambic已从科技和医疗保健领域的投资者处筹集了4.618亿美元。根据申报文件，Catalio Capital Management的持股比例将从11%降至8.9%，而Nexus Venture Partners的持股比例将从8.5%降至6.8%。申报文件还显示，英伟达曾参与Iambic多轮可转换优先股融资。
Iambic has raised $461.8 million from both technology and healthcare-focused investors since the firm was founded in 2019. Catalio Capital Management’s stake is expected to fall to 8.9% after the offering from 11%, while Nexus Venture Partners will have 6.8%, down from 8.5%, according to the filing. Nvidia participated in several of Iambic’s convertible preferred stock financings, the filing shows.
此次发行由摩根大通公司、杰富瑞金融集团公司、美国银行公司和花旗集团公司牵头。公司预计将于周四在纳斯达克全球精选市场以股票代码IAM进行交易。
The offering is being led by JPMorgan Chase & Co., Jefferies Financial Group Inc., Bank of America Corp. and Citigroup Inc. The company expects to trade Thursday on the Nasdaq Global Select Market under the symbol IAM.